%0 Journal Article
%A Ehret, Felix
%A Wolfgang, Josy
%A Allwohn, Luisa
%A Onken, Julia
%A Wasilewski, David
%A Roohani, Siyer
%A Oertel, Joachim
%A Zips, Daniel
%A Kaul, David
%T Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation.
%J Clinical and translational radiation oncology
%V 42
%@ 2405-6308
%C Amsterdam
%I Elsevier
%M DKFZ-2023-01517
%P 100653
%D 2023
%X Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the World Health Organization classification of central nervous system tumors, studies in isocitrate dehydrogenase wild type (IDH-wt) cohorts undergoing a second course of radiotherapy remain limited. Herein, we sought to describe our institutional experience and outcomes after GBM IDH-wt re-irradiation.GBM patients with confirmed IDH-wt status undergoing re-irradiation were included in this single-center, retrospective analysis.A total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 4.6 months and 4.4 months, respectively. Most patients had a Karnofsky performance status of at least 80
%K Glioblastoma (Other)
%K IDH (Other)
%K Isocitrate Dehydrogenase (Other)
%K Radiation Necrosis (Other)
%K Radionecrosis (Other)
%K Radiotherapy (Other)
%K Re-irradiation (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37502699
%2 pmc:PMC10369398
%R 10.1016/j.ctro.2023.100653
%U https://inrepo02.dkfz.de/record/277806